Target intelligence / Profile preview

Human leukocyte antigen A*11:01:Kirsten rat sarcoma viral oncogene homolog G12V neoepitope peptide complex (HLA-A*11:01:KRAS G12V)

Target
HLA-A*11:01:KRAS G12V
Molecular classification
Peptide-MHC complex, Antigen-presenting molecule, Major Histocompatibility Complex (MHC) Class I
01

Overview

The Human leukocyte antigen A*11:01:Kirsten rat sarcoma viral oncogene homolog G12V neoepitope peptide complex is a specific peptide-major histocompatibility complex (pMHC) that presents a mutated fragment of the KRAS protein on the surface of cancer cells. KRAS is a key signaling protein, and its G12V mutation is a prevalent driver in aggressive malignancies such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer, often associated with poor prognosis and resistance to standard therapies (NIH, 2023). In individuals with the HLA-A*11:01 allele, the mutated KRAS peptide (typically the 9-mer VVGAVGVGK or 10-mer VVVGAVGVGK) is displayed for recognition by the immune system (Myrio Tx, 2025). This complex serves as a "public neoantigen," providing a highly specific target for adoptive cell therapies such as TCR-engineered T-cells (e.g., NW-301V) and bispecific T-cell engagers (TCEs) (ESMO, 2025; Affini-T, 2024). These therapeutic approaches aim to redirect T-cell cytotoxicity specifically toward tumor cells while sparing healthy tissues. However, a critical safety concern is the potential for off-target cross-reactivity with similar self-peptides, such as those from the RAB7B protein, which requires rigorous screening of TCR candidates (NIH, 2025). Additionally, the low density of these complexes on the tumor surface and the potential for HLA downregulation present ongoing challenges for achieving durable clinical responses (JCI, 2025).

Other names
KRAS G12V/HLA-A*11:01 complexHLA-A11:01-KRAS-G12VKRAS G12V neoantigen-HLA complexpMHC complexHLA-A*11:01:KRAS G12V 9-mer complexHLA-A*11:01:KRAS G12V 10-mer complex
02

Mechanism of action

The complex acts as a specific ligand for engineered T-cell receptors (TCRs) or TCR-like antibodies. Upon binding, it facilitates the formation of an immunological synapse between the effector T-cell and the tumor cell, leading to T-cell activation, secretion of pro-inflammatory cytokines such as interferon-gamma and interleukin-2, and the release of cytotoxic molecules like perforin and granzymes, which induce tumor cell apoptosis.

03

Biological functions

Antigen presentationT-cell activationImmune surveillanceCytotoxic T-lymphocyte mediated killing
04

Disease associations

CancerPancreatic ductal adenocarcinomaColorectal cancerNon-small cell lung cancer
05

Safety considerations

Off-target toxicity due to cross-reactivity with self-peptides (e.g., RAB7B)Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)HLA downregulation or loss as a resistance mechanismLow antigen density on the tumor cell surface
06

Interacting drugs

NW-301V

4 more in the full profile.

07

Biomarkers

HLA-A*11:01 genotypeKRAS G12V mutation statusInterferon-gamma (IFN-gamma) secretionCD137 expression on T cells

Beyond the preview

Go deeper on Human leukocyte antigen A*11:01:Kirsten rat sarcoma viral oncogene homolog G12V neoepitope peptide complex (HLA-A*11:01:KRAS G12V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human leukocyte antigen A*11:01:Kirsten rat sarcoma viral oncogene homolog G12V neoepitope peptide complex (HLA-A*11:01:KRAS G12V).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call